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An active arena for technological advancement in
radiation oncology treatment delivery has focused on the
motion inherent in target structures and normal organs.
With the advances over the last decade (and more so
within the last few years), in intensity modulated
radiation therapy (IMRT), stereotactic radiosurgery
(SRS)/radiotherapy and stereotactic body radiotherapy
(SBRT), and image-guided radiation therapy, it has
become critical to position patients in the treatment
positions precisely and reproducibly. To address theseConflicts of interest: None.
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doi:10.1016/j.prro.2011.10.005localization issues, devices have been developed that may
be implanted in the organ or volume of interest and
tracked during and between treatments
The goal of this report is to provide a review of
nonionizing technologies designed to continuously local-
ize the tumor, patient, or a surrogate. This report is
concerned only with the completely independent (non-
ionizing) systems and not systems with integrated
stereoscopic X-rays nor in house systems. Specifically,
the 3 motion management systems that were Federal Drug
Administration-approved and commercially available as of
the closure date of this report (June 17, 2008) are
discussed: the Calypso 4D (4-dimensional) Localization
System as well as the RadioCameras (ZMed Inc/Varian
Medical Systems, Ashland, MA) and the AlignRT system
(VisionRTTM, London, UK).
Continuous localization systems are highly specialized
technologies that require a significant quality assurancelsevier Inc. Open access under CC BY-NC-ND license. 
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Given the scope of quality issues involved, the quality
assurance program would need to address setup, testing,
maintenance and interoperability of equipment, treatment
planning, patient positioning, and process of care, as well
as staffing, education, training, and appropriate supervi-
sion. While important, these aspects of target localization
are outside the scope of this paper. Additional detail is
available in the full Emerging Technology Committee
report, which is available on the American Society for
Radiation Oncology website (www.astro.org).Description of the currently marketed devices
Calypso 4D localization system
The Calypso system uses an array of AC magnetic coils
to generate a resonant response in implanted transponder
beacons that is subsequently detected using a separate
array of receiver coils. The beacons are inserted within the
prostate gland under ultrasound guidance in a manner
analogous to a needle biopsy,1 prior to computed
tomographic (CT) simulation. Typically 3 are implanted,
though the system can use as few as 2. Transponder
coordinates on the CT scan relative to the treatment plan
isocenter are determined and entered into the Calypso
system. The location of the array is tracked in the treatment
room using 3 ceiling-mounted infrared cameras. The
system then monitors the intrafraction movement of the
beacons relative to the calibrated isocenter during each
treatment. Individual facilities may choose to relocalize the
patient or interrupt treatment based on the observed
intrafraction motion. This report focuses on the published
literature as it applies to prostate localization as this
represents the only currently Federal Drug Administration-
approved indication.
RadioCameras
The RadioCameras system is specifically designed for
intracranial radiosurgery with high-precision patient
positioning.2 The system uses 2, two-dimensional
charged couple devices that detect movement in a rigid
array containing 4 infrared, passively reflective markers.
The cameras are rigidly mounted in the ceiling of a
treatment room and interfaced with a personal computer.
The infrared markers fixed to the array are connected
with the patient by rigid attachment of the array to a
custom maxillary bite-block. The patient is CT-simulated
with the bite-block in place and is registered in the
treatment room in 3 dimensions by the passive infrared
system. The camera system must be able to identify at
least 3 of the 4 markers to determine the array's position
and a software application will then display thedisplacement (with 0.1-mm precision) of the patient,
along with the rotations (yaw, pitch, and roll with 0.1
degree precision) for each treatment. The system is used
for frameless SRS/SBRT of the head and neck or central
nervous system.2
AlignRT
The AlignRT system uses a ceiling-mounted camera
system to create a 3-dimensional topographic patient
surface rendering that can be tracked for positioning
during treatment. This is accomplished by registering the
patient's unique 3D surface pattern using a system of
special cameras and flashes. The 3D reference surface can
be acquired during CT simulation scan or on the first day
of treatment. Prior to each treatment the patient surface
rendering is acquired and compared with the reference
surface to make any daily changes in 6 degrees. This can
also be done in a real-time continuous mode that allows for
intrafraction monitoring. The data for this system have
been used for breast cancer treatment.Description of patients potentially benefiting
from use of technology
It seems intuitive that the use of “continuous
localization technologies” would be implemented hand-
in-hand with the use of advanced radiotherapy planning
and delivery techniques (eg, IMRT, SBRT, SRS, etc).
The ability to conform the radiation dose distribution to
the target(s) of interest while sparing surrounding normal
tissues has the potential to reduce the margin for error
with respect to localization uncertainty. The inability to
localize appropriately may result in a geographic miss of
the intended target tissues. The use of continuous
localization technologies also has the potential to reduce
normal tissue side effects as well as improve outcomes if
able to correct for inaccurate targeting of advanced
delivery techniques.
Tumors located in the pelvis, abdomen, and thorax
are subject to motion during treatment caused by
respiration, inherent bowel mobility and peristalsis, and
cardiac motion. This motion is often accounted for by
applying a margin to the target of interest to encompass
the spatial variability of the target. However, treatment
of this margin results in the delivery of unwanted dose
to normal tissues when the target is not occupying a
given position. The use of real-time tracking techniques
may allow for a reduction in this margin and thus has
the potential to reduce the morbidity associated with
unnecessary dose to surrounding normal tissues. There
is potential for all patients undergoing radiotherapy to
the aforementioned body sites to benefit from real-time
tracking techniques.
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existing studiesCalypso 4D localization system
There have been several articles published on the use
of the Calypso system both in phantom studies as well
as in patients. These clinical studies have focused
primarily on prostate cancer. In phantom measurements,
Balter et al1 observed sub-millimeter localization and
tracking capabilities of the Calypso system, with values
that remained stable over prolonged periods of time.
These results have been updated recently by Litzenberg
et al.3 Willoughby et al,4 in reporting on the first human
use of the system, evaluated the localization accuracy of
the Calypso system relative to radiographic localization,
and assessed its ability to track prostate motion in real
time. Their findings indicated significant intrafraction
prostate motion (greater than 10 mm) in 2 of 11
patients.4 The Calypso system demonstrated comparable
(within 2 mm) isocenter localization accuracy compared
with X-ray localization procedures.4 Kupelian et al5
reported on Calypso-based localization and continuous
real-time monitoring of the prostate gland on a multi-
institutional trial consisting of 41 patients treated at 5
institutions. They found differences between skin marks
versus Calypso alignment to be greater than 5 mm in
vector length in more than 75% of all fractions. They
also observed that individual patients exhibited displace-
ments of 5 mm or more, lasting at least 30 seconds, in
56% of all fractions. Using the criterion that 90% of
patients receive 95% of the prescribed dose within the
PTV, Litzenberg6 showed that margins required to
accommodate intrafraction motion were approximately
2 mm in all directions, assuming that Calypso-based
localization was performed for each fraction prior to the
start of treatment. In the absence of Calypso-based
localization these margins are approximately 10 mm,
indicating that a substantial reduction in margins is
possible when daily alignment is performed using the
Calypso system.6 A recent study7 showed that when
Calypso is used for daily localization, the setup
uncertainty is reduced enough that planning treatment
volumes can be reduced significantly without compro-
mising dosimetric coverage.
The efficacy of Calypso localization among patients
receiving androgen ablation therapy is not well defined.
One small comparative study of 41 patients in which 14
received neoadjuvant and concurrent androgen suppres-
sion found that the implanted electromagnetic markers
maintained a stable geometry within the prostate gland
over time, both in patients treated with androgen depri-
vation and in patients treated with radiation therapy alone.8
The impact of the electromagnetic detector array on the
quality of radiation beams and portal images is of potentialconcern, as the array is placed several centimeters above
the patients during treatment to detect signals from the
transponders. Preliminary research demonstrated that the
increase in skin dose attributable to the array was “within
acceptable clinical limits”9 though this was not quantified.
Additionally, researchers found that attenuation of the
beams was less than 0.5% for radiation incident normal to
the array; no comment was made regarding oblique or
tangential beams.9 Finally, the researchers stated that
“portal image quality due to presence of the array in the
beam path was similar to that of patient support devices,
such as nylon-strung tennis racquet table inserts.”9
Researchers have also performed introductory studies
analyzing possible application of the Calypso localization
system to head and neck cancer patients. In one such study,
a dental prosthesis was cast from a volunteer and some of
the teeth were filled with dental amalgam. The prosthesis
was placed under the detection array, adjacent to 3
transponders, and the resultant measurements were
compared to those taken without the presence of the
dental prosthesis. Despite the presence of the amalgam, the
system could localize the transponders up to 20 cm from
the array.10 Placement of the transponders within a
mouthpiece does not increase backscatter dose to overly-
ing oral mucosa.11RadioCameras
The initial clinical study of this technology focused on
stereotactic radiosurgery for central nervous system
malignancies at the University of Florida.12 Sixty patients
with benign and malignant tumors received a total of
1426 treatments using this frameless SRS system. The
system proved to be robust with a misalignment vector
error of 0.18 mm; the tolerance limit of 0.3 mm and 0.3
degrees was achieved in every case. This accuracy was
determined to rival frame-based systems. Two follow-up
studies have further evaluated this technology.13,14 The
most recent study followed 64 patients who received
frameless stereotactic radiosurgery for intracranial meta-
static disease. Some of the patients were treated up front
and others for progressive disease after initial resection
or whole brain radiotherapy.
The authors noted the advantage of the system being no
pain or discomfort to the patient, ability to perform
treatment planning and treatment delivery on different
days, and reduction of resource utilization, personnel, cost,
and complexity of the stereotactic procedure.14 The main
disadvantage of the technique was noted to involve the
potential for lengthy treatment times. Because of the use
of conventional linac-based machines, treatment times
were about 15 minutes per isocenter. Patients requiring
more than 4 isocenters were found to be technically
challenging and otherwise not good candidates because
of patient fatigue during the lengthy treatment times.
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in ten patients with advanced head and neck cancers.15
These patients were prospectively enrolled to determine
the potential impact of traditional daily setup variations
with laser alignment and immobilization mask markings.
The passive fiducial arrays were mounted to the
maxillary bite-tray and acted as the “gold-standard.”
They found an average composite mean vector error of
6.97 mm±3.63 mm with conventional methods. Based
on these findings, the authors noted that the gross tumor
volume and planning target volume were underdosed
and critical normal structures like the parotid or globe
were overdosed utilizing IMRT with conventional daily
patient alignment.
AlignRT
Most of the data for the AlignRT system have been
provided during talks or supplemental abstracts and have
primarily been related to the setup of breast cancer
patients.16-29 The Massachusetts General Hospital used
the system to assess its utility in patient setup for APBI
(accelerated partial breast irradiation).18 The accuracy of
the system (in 9 patients) was compared with traditional
laser and portal image patient setup. Mean 3-dimensional
displacements were 7.3±4.4 mm and 7.6±4.2 mm for laser
and portal image setup, respectively, as compared with
1.0±1.2 mm for AlignRT. Breathing motion datum at
isocenter was 1.9±1.1 mm. As a comparison, the system
was used to evaluate the surface motion of the abdomen
and 5.7±1.3 mm of displacement was noted. Other sites
explored in abstracts noted increased accuracy in posi-
tioning the head for use in stereotactic radiosurgery
guidance.21,25
Good correlation has been noted between surface and
bony anatomy.19 The practical utility of the system may
be limited by skin-to-tumor positional correlation, which
was investigated in one abstract for the case of APBI,22
where the registration of lumpectomy-site clip-based
imaging (“gold standard”) was compared with the skin
alignment assessed by AlignRT. Both agreed within 1 mm,
suggesting that the surface of the breast may be a
reasonable surrogate for the treatment volume.Identification, analysis, and evaluation of
consequences of nonuse
The inability to localize appropriately when using
advanced radiation delivery techniques may result in a
geographic miss of the intended target tissues, resulting in
uncertainties with respect to tumor control. Additionally, a
geographic miss of the target(s) generally results in the
unintended delivery of high dose to healthy tissues and has
the potential to result in unexpected additional morbidity.The use of real-time tracking techniques has the
potential to limit morbidity by decreasing the dose to
normal structures through the reduction of target margins
utilized for spatial uncertainty. Not employing tracking
techniques, whether ionizing or nonionizing, makes it
imperative that these margins be applied in order to
maintain treatment outcomes gained to date.
Previous localization and tracking techniques typically
utilize ionizing radiation. A notable exception is the
use of ultrasound, although to date this usage is limited
to a few tumor sites. None of the technologies evaluated
in this study involve the use of ionizing radiation.Future prediction based on
technology development
Given the growing popularity of dose escalation,
hypofractionation, and respiratory gating, and the potential
improvement of clinical outcomes from each, it can be
postulated that the use of real-time tracking techniques will
increase in the radiation oncology community. Through
further research and clinical trials, the Calypso system
is being expanded to use in body sites outside the pelvis,
which may lead to its use on a more routine basis for
a larger population of patients.
The use of technologies that allow the registration of
patient topography for use with respiratory gating will also
likely increase. Current gating systems suffer from the
uncertainty of correlation of external markers with internal
structure movement. It may be that the increase in the
number of registration points (the body surface) will
decrease these uncertainties.
There are 2 main areas of clinical outcomes improve-
ment that may be expected as a result of more accurate
real-time localization using these technologies. The first
involves target localization, in which the treatment fields
are centered on a per-fraction basis on the center of mass of
the target volume itself, as opposed to stable but unrelated
bony or other anatomic landmarks. Use of unrelated
landmarks requires the use of wider margins around the
target volume, as described in this report, and thesemargins
must be particularly large in the case of very mobile targets,
including tumors located in the thorax and abdomen. These
same tumors generally have poor outcomes overall, and
this is in part due to the inability to escalate dose to large
volumes of the surrounding normal tissues. Therefore the
use of real-time continuous localization techniques may
allow for clinically relevant reduction in margins, which
will then allow for reduced normal tissue dose-volumes and
subsequently dose escalation to the target volume that may
lead to improved tumor control. These are the next phase
of clinical trials which need to be conducted to verify
outcomes following the implementation of continuous
localization technologies.
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clinical outcomes involves dose to normal tissue. Radia-
tion toxicity to normal tissue is directly related to the
volume of the normal tissue that receives any given per-
centage of the prescribed dose. This outcome is important
for all treatment sites, even in the case of tumors that do
not exhibit a lot of inherent motion. For example, in
prostate or breast cancer, in which the tumor motion is
generally less extreme than for tumors in the thorax, and in
which dose escalation is either already feasible (prostate)
or not indicated (breast), it is still important to minimize
the dose to critical normal tissues that surround the target
volumes in order to reduce acute and especially long-term
toxicity. Many patients with prostate and breast cancer will
enjoy normal life spans after treatment; therefore the
avoidance of late toxicities to the bowel, bladder, lung, and
heart should contribute to quality of life and reduce the
cost of post-treatment care. In addition, the feasibility of
hypofractionation depends upon the ability to very
accurately localize the target volume with minimal mar-
gins, as treatment of large volumes of the surrounding
normal tissues would result in a higher likelihood of
developing late toxicities due to the large dose per fraction
used in these regimens. Hypofractionation, therefore, is
highly dependent upon technologies that allow precise
and real-time target localization in order to reduce normal
tissue dose volumes. While the demonstration of reduced
late toxicity may take many years to demonstrate in
clinical trials, these outcomes should also be examined. In
the interim, patients may well benefit from the use of
continuous localization techniques as a component of
image guided radiotherapy, and their use should be
considered one method for achieving greater accuracy
and precision.References
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